Patent application number | Description | Published |
20090291448 | Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 11-26-2009 |
20100184063 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 07-22-2010 |
20110224313 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 09-15-2011 |
20120004116 | METHODS FOR BIOMARKER IDENTIFICATION AND BIOMARKER FOR NON-SMALL CELL LUNG CANCER - There is provided a method for identifying a biomarker, such as a gene signature, associated with a biological parameter A 6-gene signature for non-small cell lung cancer (NSCLC) is also provided, as well as a method of prognosing or classifying a subject with non-small cell lung cancer into a poor survival group or a good survival group, using said gene signature | 01-05-2012 |
20120100999 | PROGNOSTIC GENE EXPRESSION SIGNATURE FOR SQUAMOUS CELL CARCINOMA OF THE LUNG - Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A. | 04-26-2012 |
20120141603 | METHODS AND COMPOSITIONS FOR LUNG CANCER PROGNOSIS - Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy. | 06-07-2012 |
20120225954 | METHODS AND COMPOSITIONS FOR THE CLASSIFICATION OF NON-SMALL CELL LUNG CARCINOMA - The disclosure includes a method of screening for, diagnosing or detecting non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma in a subject. The method comprises:
| 09-06-2012 |
20120323594 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 12-20-2012 |
20130065789 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 03-14-2013 |